Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Burrill Predicts Better Time' Ahead For Biotech Industry

Sep. 25, 2003

By Aaron Lorenzo

Burrill Predicts Better Time' Ahead For Biotech Industry

Sep. 25, 2003

By Aaron Lorenzo

ParAllele's Second Round Raises $22.5M For Commercial Growth

Sep. 24, 2003

By Aaron Lorenzo

Anticipating Ceplene Approval, Maxim Raises $25.5M Privately

Sep. 24, 2003

By Aaron Lorenzo

ParAllele's Second Round Raises $22.5M For Commercial Growth

Sep. 24, 2003

By Aaron Lorenzo

Anticipating Ceplene Approval, Maxim Raises $25.5M Privately

Sep. 24, 2003

By Aaron Lorenzo

First-Round Financing Of $12.5M Puts Ambrx On Development Path

Sep. 23, 2003

By Aaron Lorenzo

First-Round Financing Of $12.5M Puts Ambrx On Development Path

Sep. 23, 2003

By Aaron Lorenzo

IntraBiotics Receives FDA Nod To Proceed With Pivotal Trials

Sep. 22, 2003

By Aaron Lorenzo

Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)

IntraBiotics Receives FDA Nod To Proceed With Pivotal Trials

Sep. 22, 2003

By Aaron Lorenzo

Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...